Inflammasome Therapeutics

Anti-inflammatory drugs have come a long way since the advent of corticosteroids. While they marked a pivotal moment in the 20th century for managing devastating inflammation, non-steroidal anti-infla

In an interview with Scrip , Boehringer Ingelheim International GmbH ’s top business development executives offered their views on conducting transactions amid a pandemic, why a company usually focus

Germany’s family-owned multinational Boehringer Ingelheim International GmbH (BI) is acquiring preclinical antibody assets from two biotechs, Canada’s Northern Biologics Inc. and Switzerland’s CD

Deals In September BI, Inflammasome Ally In $160m Retinal Diseases Collaboration Boehringer Ingelheim International GmbH and Inflammasome Therapeutics Inc. agreed to co-develop up to three candida